(Q34322778)

1 August 2017

1 reference

title

Letrozole: a review of its use in postmenopausal women with breast cancer (English)

1 reference

1 August 2017

3

Caroline M Perry

1 reference

1 August 2017

2

Monique P Curran

1 reference

1 August 2017

Dene Simpson

1

1 reference

1 August 2017

publication date

1 January 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

64

1 reference

1 August 2017

issue

11

1 reference

1 August 2017

page(s)

1213-1230

1 reference

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 August 2017

cites work

1 reference

12 December 2020

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer

1 reference

12 December 2020

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

1 reference

12 December 2020

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

12 December 2020

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

1 reference

12 December 2020

Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer

1 reference

12 December 2020

Intratumoral aromatase model: the effects of letrozole (CGS 20267)

1 reference

12 December 2020

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

12 December 2020

Pharmacokinetics of third-generation aromatase inhibitors.

1 reference

12 December 2020

Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens

1 reference

12 December 2020

Letrozole in breast cancer

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Letrozole: updated duration of response

1 reference

12 December 2020

The current status of aromatase inhibitors in the management of breast cancer

1 reference

12 December 2020

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

1 reference

12 December 2020

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

12 December 2020

Letrozole. A review of its use in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells

1 reference

12 December 2020

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

12 December 2020

Critics question price of success in halted clinical trial of aromatase inhibitor letrozole

1 reference

12 December 2020

Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients

1 reference

12 December 2020

Endocrine therapy of advanced disease: analysis and implications of the existing data.

1 reference

12 December 2020

A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.

1 reference

12 December 2020

Letrozole in the treatment of breast cancer

1 reference

12 December 2020

Aromatase inhibitor development and hormone therapy: a perspective

1 reference

12 December 2020

Advanced breast cancer: an update and controversies on diagnosis and therapy

1 reference

12 December 2020

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1 reference

12 December 2020

Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Are patients diagnosed with breast cancer before age 50 years ever cured?

1 reference

12 December 2020

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

12 December 2020

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer

1 reference

12 December 2020

Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor

1 reference

12 December 2020

Aromatase inhibitors in early breast cancer treatment

1 reference

12 December 2020

Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy

1 reference

12 December 2020

Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.

1 reference

12 December 2020

Letrozole after Tamoxifen for Breast Cancer — What Is the Price of Success?

1 reference

12 December 2020

Absolute bioavailability of letrozole in healthy postmenopausal women

1 reference

12 December 2020

The pharmacology of letrozole

1 reference

12 December 2020

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

12 December 2020

Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.

1 reference

12 December 2020

The effects of aromatase inhibitors and antiestrogens in the nude mouse model

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

12 December 2020

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer

1 reference

12 December 2020

Clinical pharmacokinetics of aromatase inhibitors and inactivators

1 reference

12 December 2020

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

12 December 2020

Endocrine therapy in the treatment of metastatic breast cancer

1 reference

12 December 2020

Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.

1 reference

12 December 2020

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

1 reference

12 December 2020

The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.

1 reference

12 December 2020

Long-term medical costs of postmenopausal breast cancer therapy

1 reference

12 December 2020

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

1 reference

12 December 2020

Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole

1 reference

12 December 2020

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

12 December 2020

Local endocrine effects of aromatase inhibitors within the breast

1 reference

12 December 2020

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

1 reference

12 December 2020

A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

1 reference

12 December 2020

New generation aromatase inhibitors in breast cancer. Weighing out potential costs and benefits

1 reference

12 December 2020

Aromatase inhibitors in breast cancer

1 reference

12 December 2020

Efficacy and economics of hormonal therapies for advanced breast cancer

1 reference

12 December 2020

Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada

1 reference

12 December 2020

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

1 reference

12 December 2020

Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen

1 reference

12 December 2020

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

1 reference

12 December 2020

Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

The role of aromatase inhibitors in the treatment of metastatic breast cancer

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer

1 reference

12 December 2020

Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.

1 reference

12 December 2020

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.

1 reference

12 December 2020

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status

1 reference

12 December 2020

Annual hazard rates of recurrence for breast cancer after primary therapy.

1 reference

12 December 2020

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

12 December 2020

10.2165/00003495-200464110-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1037865192

0 references

1 reference